for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Elanco Animal Health Inc

ELAN.N

Latest Trade

32.63USD

Change

0.16(+0.49%)

Volume

352,878

Today's Range

32.36

 - 

32.72

52 Week Range

25.77

 - 

37.46

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
32.47
Open
32.47
Volume
352,878
3M AVG Volume
79.17
Today's High
32.72
Today's Low
32.36
52 Week High
37.46
52 Week Low
25.77
Shares Out (MIL)
473.02
Market Cap (MIL)
15,358.93
Forward P/E
31.71
Dividend (Yield %)
--

Next Event

Dividend For ELAT.N - 0.6250 USD

Latest Developments

More

Elanco Animal Health Reports Second Quarter 2021 Results

Elanco Announces Agreement To Buy Kindred Biosciences

TriRx Enters Agreement For The Acquisition Of Elanco Animal Health Facilities

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Elanco Animal Health Inc

Elanco Animal Health Incorporated is an animal health company that develops, manufactures and markets products for companion and food animals. The Company offers its products under four primary categories, such as Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. It provides a range of parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. It also offers a pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. It also provides treatments for otitis (ear infections), as well as cardiovascular and dermatology indications. Its portfolio in Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics. It also provides products in poultry and aquaculture production.

Industry

Biotechnology & Drugs

Contact Info

2500 Innovation Way N

GREENFIELD, IN

46140-9163

United States

https://www.elanco.com/

Executive Leadership

R. David Hoover

Independent Chairman of the Board

Jeffrey N. Simmons

President, Chief Executive Officer, Director

Todd S. Young

Chief Financial Officer, Executive Vice President

Racquel Harris Mason

Executive Vice President and Chief Marketing Officer, Elanco Animal Health

David S. Kinard

Executive Vice President, Human Resources Corporate Affairs and Administration

Key Stats

2.21 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

3.1K

2019

3.1K

2020

3.3K

2021(E)

4.7K
EPS (USD)

2018

1.180

2019

1.060

2020

0.470

2021(E)

1.003
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.38
Price To Book (MRQ)
1.92
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
76.40
LT Debt To Equity (MRQ)
69.45
Return on Investment (TTM)
-6.10
Return on Equity (TTM)
-5.46

Latest News

Latest News

Elanco says flea, tick collars safe amid pressure to recall product

Elanco Animal Health Inc said on Friday it was backing the safety of its popular pet collars to repel flea and ticks after a Congressional subcommittee asked for the product to be recalled following reports linking it to hundreds of pet deaths.

Elanco stands behind safety of its flea and tick collars

Elanco Animal Health Inc said on Friday it stood behind the safety of its Seresto collars for flea and ticks after a Congressional subcommittee asked for the product to be removed from the market.

Starboard takes stake in Elanco, nominates three directors to board - WSJ

Hedge fund Starboard Value LP has taken a stake in Elanco Animal Health Inc and nominated three directors to the animal healthcare company's board, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.

Starboard takes stake in Elanco, adds three directors to board: WSJ

Hedge fund Starboard Value LP has taken a stake in Elanco Animal Health Inc and nominated three directors to the company's board, the Wall Street Journal reported on Wednesday, citing people familiar with the matter. (https://on.wsj.com/3sYWlof) (Reporting by Mrinalika Roy...

Sachem Head takes $1.2 billion position in Elanco, stock price surges

Hedge fund Sachem Head Capital Management said on Wednesday that it owns a $1.2 billion stake in Elanco Animal Health Inc and plans to push for changes at the company that makes medicines and vaccinations for pets and livestock.

Elanco to cut over 900 positions in first reorganization since Bayer unit deal

Elanco Animal Health Inc <ELAN.N> said on Wednesday it would cut more than 900 positions across nearly 40 countries, in the first restructuring action since the closing of its $6.89 billion acquisition of Bayer's <BAYGn.DE> veterinary drugs unit.

Elanco Animal Health to cut over 900 positions to lower costs

Elanco Animal Health Inc said on Wednesday it would cut more than 900 positions across nearly 40 countries, in the first restructuring action since the closing of its $6.89 billion buyout of Bayer's veterinary drugs unit.

Elanco's Brazil unit taps new executive as $6.89 billion Bayer deal concluded

Sérgio Schuler was appointed director general of Elanco Animal Health Inc's <ELAN.N> Brazil unit after the U.S.-based veterinary products firm completed its acquisition of Bayer's <BAYGn.DE> animal health division on Monday.

Elanco Animal Health wins approval to buy Bayer unit

Elanco Animal Health <ELAN.N> has won U.S. antitrust approval to buy Bayer AG's <BAYGn.DE> animal health business on condition that it sell assets to treat three ailments, two in dogs and one in cattle, the Federal Trade Commission said on Wednesday.

Elanco to divest brands, forgo Canadian rights for Bayer's unit deal

Elanco Animal Health Inc <ELAN.N> has decided against acquiring Bayer AG's Canadian distribution rights to several poultry insecticides, Canada's Competition Bureau said on Tuesday, as it looks to complete a $7.6-billion deal.

BRIEF-Elanco Animal -Entered Into Amendment No. 3 To Certain Share And Asset Purchase Agreement Dated As Of August 20

* ELANCO ANIMAL HEALTH- ENTERED INTO AMENDMENT NO. 3 TO CERTAIN SHARE AND ASSET PURCHASE AGREEMENT DATED AS OF AUGUST 20, 2019

BRIEF-Elanco Announces European Commission Approval Of Pending Acquisition Of Bayer Animal Health

* ELANCO ANNOUNCES EUROPEAN COMMISSION APPROVAL OF PENDING ACQUISITION OF BAYER ANIMAL HEALTH

Elanco wins conditional EU antitrust okay for $7.6 billion Bayer deal

Elanco Animal Health <ELAN.N> secured EU antitrust clearance on Monday to buy Bayer's <BAYGn.DE> veterinary drugs unit after pledging to sell some products to address competition concerns about the $7.6 billion deal.

BRIEF-Elanco Animal Health Reports Q1 Adjusted Earnings Per Share $0.13

* Q1 REVENUE $657.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $718.4 MILLION

BRIEF-Elanco Expands Executive Team To Lead Company Post Bayer Animal Health Acquisition

* ELANCO EXPANDS EXECUTIVE TEAM TO LEAD COMPANY POST BAYER ANIMAL HEALTH ACQUISITION

BRIEF-Elanco Animal Health Submits Form Co To European Commission

* ELANCO ANIMAL HEALTH SUBMITS FORM CO TO EUROPEAN COMMISSION

BRIEF-Elanco, Vetnow Collaborate To Expand Access To Veterinary Care

* ELANCO, VETNOW COLLABORATE TO EXPAND ACCESS TO VETERINARY CARE, RELIEVE IMPACT OF COVID-19 Source text for Eikon: Further company coverage:

BRIEF-Elanco Animal Health Says CEO Jeffrey Simmons 2019 Total Compensation Was $15.8 Mln Versus $5.4 Mln In 2018

* ELANCO ANIMAL HEALTH SAYS CEO JEFFREY SIMMONS 2019 TOTAL COMPENSATION WAS $15.8 MILLION VERSUS $5.4 MILLION IN 2018 - SEC FILING

BRIEF-UK's CMA Invites Comments On Dechra Pharmaceuticals, Elanco Animal Health

* UK'S CMA INVITES COMMENTS ON ANTICIPATED ACQUISITION BY DECHRA PHARMACEUTICALS PLC OF OSURNIA BUSINESS OF ELANCO ANIMAL HEALTH INCORPORATED

BRIEF-Elanco Animal Health Withdraws Its Previously Announced 2020 Revenue And EPS Guidance

* ELANCO ANIMAL HEALTH INC - WITHDRAWING ITS PREVIOUSLY ANNOUNCED 2020 REVENUE AND EARNINGS PER SHARE GUIDANCE.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up